Colombia Market Basics for Chinese Medical Device Manufacturers

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Colombia has a population of about 52 million and operates the SGSSS universal health coverage system (EPS insurers plus IPS service providers). Third-party estimates put its medical device market at roughly USD 1.5 to 2 billion, IVDs at about USD 300 million, annual growth at about 5–6 percent, and import dependence at about 80–85 percent. These figures make one point clear: Colombia is a market that relies heavily on imports while providing payment coverage for the entire population.

For Chinese manufacturers, the real attraction lies on the institutional-cost side. Device registration certificates are uniformly valid for 10 years, Class I/IIa go through automatic registration with an official review timeline of only 2 business days, and the renewal window opens at least 3 months before expiry. Based on market quotation ranges (practical estimate), the full-package registration cost per product is about USD 2,000–3,000. The GRZAN regulatory team’s judgment is that when amortized over a ten-year validity, Colombia offers one of the lowest per-period compliance costs among major Latin American entry points.

2. Legal basis

RegulationInstrument numberDate of publicationArticle provisions
Decree establishing the health registration, marketing authorization and health surveillance regime for medical devices for human use (Decreto 4725 de 2005)Decreto 4725 de 20052005-12-26Art. 16, Art. 17 (registration pathways); validity 10 years
Decree amending Decreto 4725 de 2005 (Decreto 582 de 2017)Decreto 582 de 20172017-04-04Art. 32 (automatic renewal for Class I/IIa)
2026 fee schedule (Manual Tarifario)Resolución 20250675432025-12-22Class I/IIa 321.91 UVB ≈ COP 3,898,330; Class IIb/III 364.36 UVB ≈ COP 4,413,000
Manual of requirements for storage and conditioning capacity (Manual de Requisitos de Capacidad de Almacenamiento y Acondicionamiento)Resolución 4002 de 2007Published in 2007CCAA valid 5 years; importers must employ a technical director; request re-inspection at least 5 business days before expiry
National Technovigilance Program (Programa Nacional de Tecnovigilancia)Resolución 4816 de 2008Published in 200872-hour reporting of serious adverse events, quarterly periodic reports
Semantic standard and UDI-DI coding requirementsResolución 1405 de 20222022-08-08Applies to devices and IVDs; semantic report fully mandatory from 2026-03-12

3. Expert insights

#### Import dependence shapes the regulatory posture and the friendliness of market access

Import dependence of roughly 80–85 percent (third-party estimates) means Colombia’s domestic supply capacity is limited and the regulator’s core objective is to bring necessary products in, not to restrict imports. This explains why Class I/IIa go through automatic registration with a 2-business-day review and why Art. 32 permits automatic renewal. The GRZAN regulatory team views this easy-entry, strict-oversight pattern as a structural benefit for Chinese manufacturers, but the benefit has limits — the easy entry applies to low- and medium-risk products, while high-risk Class IIb/III still face 90 business days of standard registration, and easier entry does not mean relaxed technical requirements.

#### The share of Chinese manufacturers in the INVIMA database shows competition has turned white-hot

According to third-party statistics, the INVIMA registration database holds about 423,000 records, of which Chinese manufacturers account for about 61,000, or 14.4 percent. That share shows Chinese suppliers are no longer newcomers in Colombia but one of the main sources of supply. The GRZAN judgment is that when the supply side is this concentrated, price competition has little room left, and differentiation should shift toward compliance quality — the completeness of UDI and semantic reporting, the timeliness of vigilance reports, and responsiveness to corrections are the variables that stand out within that crowded 14.4 percent.

#### Ten-year validity plus low cost makes certificates worth managing as long-term assets, with a ledger

At about USD 2,000–3,000 per product for full-package registration (market quotation range, practical estimate) and a 10-year validity, the annualized cost is extremely low. Yet the GRZAN regulatory team cautions that low cost invites a get-the-certificate-and-walk-away mentality, while the post-market inspections, suspension and cancellation rules introduced by Decreto 582 de 2017 and the 72-hour reporting duty under Resolución 4816 de 2008 all demand sustained investment. Companies are advised to manage certificates as an asset ledger rather than a one-time deliverable.

4. Practical recommendations

  1. The GRZAN regulatory team positions Colombia as the first Latin American stop for a regional compliance base: complete the setup of the titular and local legal representative first, then replicate the experience into neighboring markets such as DIGEMID in Peru and ANMAT in Argentina.
  2. Prioritize Class I/IIa products for the first entry, using the 2-business-day automatic registration to reach initial market presence quickly, validate channels and demand, and only then advance into Class IIb/III.
  3. Build the submission budget under Resolución 2025067543: Class I/IIa at 321.91 UVB and Class IIb/III at 364.36 UVB, reserving budget for changes of a technical nature (COP 1,060,243) and of a legal nature (COP 826,546).
  4. Before signing with an importer, verify the validity of its CCAA (5 years) and that the technical director (director técnico) is in place, and remind it to request re-inspection at least 5 business days before expiry (Resolución 4002 de 2007).
  5. Create a certificate asset ledger recording the registration number (such as INVIMA 2025DM-0002510-R2), the validity start date, the renewal window and the responsible person.
  6. Complete the semantic report and UDI-DI coding early (Resolución 1405 de 2022); the semantic report has been fully mandatory since March 12, 2026, and gaps directly block commercialization.
  7. Establish a post-market vigilance mechanism: report serious adverse events to INVIMA within 72 hours and submit periodic reports quarterly.

5. Verification checklist

  • □ An internal assessment of market size and import dependence has been completed (third-party estimates, with the basis noted)
  • □ The titular and the local legal representative (apoderado / representante legal) have been set up
  • □ The first-wave products have been chosen mainly from Class I/IIa, using the 2-business-day automatic registration pathway
  • □ The submission and change budget has been prepared under Resolución 2025067543
  • □ The importer’s CCAA has been verified as valid (5 years) and the technical director confirmed in place
  • □ A certificate asset ledger has been created (registration number, validity start date, renewal window, responsible person)
  • □ The semantic report and UDI-DI coding have been completed (Resolución 1405 de 2022)
  • □ A process for 72-hour serious adverse event reporting and quarterly periodic reporting has been established

Regulatory information verified as of October 29, 2026

All outward-facing conclusions are based on the current regulatory texts published by the competent authorities and are verified item by item before delivery.

GRZAN provides end-to-end INVIMA registration and compliance support for manufacturers entering the Colombian market, covering market-entry planning, registration budgeting, UDI and semantic reporting, importer verification and post-market vigilance. For inquiries about INVIMA registration in Colombia, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail